- AbbVie delivered adjusted earnings per share of $2.97, $0.11 above guidance midpoint, with total net revenues of $15.4 billion, exceeding expectations by over $400 million.
- Adjusted gross margin was 84.4%, R&D expense 13.7%, SG&A 21%, and operating margin 44.3%, including unfavorable impact from acquired IPR&D expense.
- Aesthetics revenues nearly $1.3 billion, down 8% due to economic challenges and lower consumer sentiment.
- HUMIRA global sales declined 58.2% due to biosimilar competition.
- Neuroscience revenues approximately $2.7 billion, up 24% operationally, led by Vraylar, BOTOX Therapeutic, Ubrelvy, and QULIPTA.
- Neuroscience revenues grew double digits, driven by Vraylar, Vyalev, and migraine portfolio.
- Oncology revenues nearly $1.7 billion with IMBRUVICA down 9.5%, Venclexta up 8.3%, and early launch of EMRELIS.
- Sales growth of 22% from ex-HUMIRA platform driven by strong performance of Skyrizi and Rinvoq, now on pace to deliver over $25 billion combined sales in 2025.
Related items and other data are not available for this feed item.